Quality of life outcomes among patients with depression after 6 months of starting treatment: Results from FINDER

Journal of Affective Disorders

Volumn 113, Issue 3, 2009, Pages 296-302

  Reed, Catherine ^a   Monz, Brigitta U ^b   Perahia, David G S ^a,c   Gandhi, Paul ^a   Bauer, Michael ^d   Dantchev, Nicolas ^e   Demyttenaere, Koen ^f   Garcia Cebrian, Ana ^a   Grassi, Luigi ^g   Quail, Deborah ^a   Tylee, Andre ^h   Montejo, Angel L ⁱ  

^a ELI LILLY AND COMPANY   (United States)

^b BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^c Gordon Hospital   (United Kingdom)

^d UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^e HÔTEL DIEU   (France)

^f UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^g UNIVERSITY OF FERRARA   (Italy)

^h KING'S COLLEGE LONDON   (United Kingdom)

ⁱ UNIVERSITY OF SALAMANCA   (Spain)

Author keywords

Antidepressants; Depression; Europe; FINDER; Quality of life; Routine practice setting

Indexed keywords

ANTIDEPRESSANT AGENT; HERBACEOUS AGENT; LITHIUM; MONOAMINE OXIDASE INHIBITOR; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TETRACYCLIC ANTIDEPRESSANT AGENT; TRICYCLIC ANTIDEPRESSANT AGENT;

ARTICLE; CONTROLLED STUDY; DEPRESSION; DISEASE DURATION; DISEASE SEVERITY; FEMALE; FOLLOW UP; HEALTH SURVEY; HOSPITAL ANXIETY AND DEPRESSION SCALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OCCUPATION; PATIENT EDUCATION; PRIORITY JOURNAL; QUALITY OF LIFE; QUALITY OF LIFE INDEX; SHORT FORM 36; SYMPTOMATOLOGY; TREATMENT OUTCOME; VISUAL ANALOG SCALE;

ADULT; ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER, MAJOR; EDUCATIONAL STATUS; EMPLOYMENT; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; QUALITY OF LIFE; QUESTIONNAIRES; SEVERITY OF ILLNESS INDEX; SOMATOFORM DISORDERS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 58749114412     PISSN: 01650327     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jad.2008.05.021     Document Type: Article

References (26)

1. Bair M.J., Robinson R.L., Eckert G.J., Stang P.E., Croghan T.W., and Kroenke K. Impact of pain on depression treatment response in primary care. Psychosom. Med. 66 (2004) 17-22
2. Barsky A.J., Wyshak G., and Klerman G.L. Hypochondriasis: an evaluation of the DSM-III criteria in medical outpatients. Arch. Gen. Psychiatry 43 (1986) 493-500
3. Brooks R., and with the EuroQoL Group. EuroQol: the current state of play. Health Policy 37 (1996) 53-72
4. Bauer M., Monz B.U., Montejo A.L., Quail D., Dantchev N., Demyttenaere K., Garcia-Cebrian A., Grassi L., Perahia D.G.S., Reed C., and Tylee A. Prescribing patterns of antidepressants in Europe: results from the Factors Influencing Depression Endpoints Research (FINDER) study. Eur. Psychiatry 23 (2008) 66-73
5. Demyttenaere K., de Fruyt J., and Huygens R. Measuring quality of life in depression. Curr. Opin. Psychiatry 15 (2002) 89-92
6. Detke M.J., Lu Y., Goldstein D.J., McNamara R.K., and Demitrack M.A. Duloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depression. J. Psychiatr. Res. 36 (2002) 383-390
7. Dunner D.L., Kwong W.J., Houser T.L., Richard N.E., Donahue R.M.J., and Khan Z.M. Improved health-related quality of life and reduced productivity loss after treatment with bupropion sustained release: a study in patients with major depression. Prim. Care Compan. J. Clin. Psychiatry 3 (2001) 10-16
8. Garcia-Cebrian A., Bauer M., Montejo A.L., Dantchev N., Demyttenaere K., Gandhi P., Grassi L., Monz B.U., Perahia D.G.S., Quail D., and Tylee A. Factors influencing depression endpoints research (FINDER): design and population characteristics. Eur. Psychiatry 23 (2008) 57-65
9. Hays R.D., Wells K.B., Sherbourne C.D., Rogers W., and Spritzer K. Functioning and well-being outcomes of patients with depression compared with chronic general medical illnesses. Arch. Gen. Psychiatry 52 (1995) 11-19
10. Kroenke K., West S.L., Swindle R., Gilsenan A., Eckert G.J., Dolor R., Stang P., Zhou X.-H., Hays R., and Weinberger M. Similar effectiveness of paroxetine, fluoxetine and sertraline in primary care. A randomized trial. JAMA 286 (2001) 2947-2955
11. Miller I.W., Keitner G.I., Schatzberg A.F., Klein D.N., Thase M.E., Rush A.J., Markowitz J.C., Schlager D.S., Kornstein S.G., Davis S.M., Harrison W.M., and Keller M.B. The treatment of chronic depression, part 3: psychosocial functioning before and after treatment with sertraline or imipramine. J. Clin. Psychiatry 59 (1998) 608-619
12. Munoz R.A., McBride M.E., Brnabic A.J., Lopez C.J., Hetem L.A., Secin R., and Duenas H.J. Major depressive disorder in Latin America: the relationship between depression severity, painful somatic symptoms and quality of life. J. Affect. Disord. 86 (2005) 93-98
13. Peveler R., Kendrick T., Buxton M., Longworth L., Baldwin D., Moore M., Chatwin J., Goddard J., Thornett A., Smith H., Campbell M., and Thompson C. A randomised controlled trial to compare the cost-effectiveness of tricyclic antidepressants, selective serotonin reuptake inhibitors and lofepramine. Health Technol. Assess. 9 (2005) 1-134
14. Pyne J.M., Patterson T.L., Kaplan R.M., Gillin J.C., Koch W.L., and Grant I. Assessment of the quality of life of patients with major depression. Psychiatr. Serv. 48 (1997) 224-230
15. Ruhe H.G., Huyser J., Swinkels J.A., and Schene A.H. Switching antidepressants after a first selective serotonin reuptake inhibitor in major depressive disorder: a systematic review. J. Clin. Psychiatry 67 (2006) 1836-1855
16. *D Study Team. Bupropion-SR, sertraline or venlafaxine-XR after failure of SSRIs for depression. N. Engl. J. Med. 354 (2006) 1231-1242
17. Saarijarvi S., Salminen J.K., Toikka T., and Raitasalo R. Health-related quality of life among patients with major depression. Nord. J. Psychiatry 56 (2002) 261-264
18. Sapin C., Fantino B., Nowicki M.L., and Kind P. Usefulness of EQ-5D in assessing health status in primary care patients with major depressive disorder. Health Qual. Life Outcomes 2 (2004) 20
19. Sobocki P., Ekman M., Ågren H., Krakau I., Runeson B., Mårtensson B., and Jönsson B. Health-related quality of life measured with EQ-5D in patients treated for depression in primary care. Value Health 10 (2007) 153-160
20. *D report. J. Clin. Psychiatry 67 (2006) 185-195
21. Tylee A., and Gandhi P. The importance of somatic symptoms in depression in primary care. Prim. Care Compan. J. Clin. Psychiatry 7 (2005) 167-176
22. Walker V., Streiner D.L., Novosel S., Rocchi A., Levine M.A., and Dean D.M. Health-related quality of life in patients with major depression who are treated with moclobemide. J. Clin. Psychopharmacol. 15 4 Suppl 2 (1995) 60-67
23. Ware J.E., Gandek B., Kosinski M., Aaronson N.K., Apolone G., Brazier J., et al. The equivalence of SF-36 summary health scores estimated using standard and country-specific algorithms in 10 countries: results from the IQOLA project. J. Clin. Epidemiol. 51 (1998) 1167-1170
24. Wells K.B., and Sherbourne C.D. Functioning and utility for current health of patients with depression or chronic medical conditions in managed primary care practices. Arch. Gen. Psychiatry 56 (1999) 897-904
25. Wells K.B., Stewart A., Hays R.D., Burnam M.A., Rogers W., Daniels M., et al. The functioning and well-being of depressed patients. Results from the Medical Outcomes Study. JAMA 262 (1989) 914-919
26. Zigmond A.S., and Snaith R.P. The Hospital Anxiety and Depression Scale. Acta Psychiatr. Scand. 67 (1983) 361-370